Verona Pharma的COPD药物Ohtuvayre在2024年销售强劲,净销售额超过4 200万美元。 Verona Pharma's COPD drug, Ohtuvayre, saw robust sales in 2024, with over $42 million in net sales.

Verona Pharma报告其COPD药物(Ohtuvare)销售额强劲,净销售额为3 600万美元(Q4 2024),全年销售额为4 200万美元。 Verona Pharma reported strong sales for its COPD drug, Ohtuvayre, with $36 million in net sales for Q4 2024 and $42 million for the full year. 2024年,有3,500多个独特的处方和16,000多个处方被填写。 Over 3,500 unique prescribers and more than 16,000 prescriptions were filled in 2024. 该公司还宣布拥有大约4亿美元的现金,并正在推进其他呼吸道治疗的研究管道。 The company also announced it has about $400 million in cash and is advancing its research pipeline for other respiratory treatments.